Oneness Biotech Co Ltd Net Assets
Oneness Biotech Co Ltd net assets. Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has net assets worth NT$10.39 Billion TWD (≈ $327.46 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$11.27 Billion ≈ $354.95 Million USD) and total liabilities (NT$872.67 Million ≈ $27.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4743 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$10.39 Billion |
| % of Total Assets | 92.25% |
| Annual Growth Rate | 15.09% |
| 5-Year Change | -25.64% |
| 10-Year Change | 315.06% |
| Growth Volatility | 54.94 |
Net Assets of Oneness Biotech Co Ltd (2009–2025)
Net assets of Oneness Biotech Co Ltd from 2009 to 2025. This chart illustrates how Oneness Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See 4743 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Oneness Biotech Co Ltd (2009–2025)
The table below shows the annual net assets of Oneness Biotech Co Ltd from 2009 to 2025. For live market cap and overall valuation, see 4743 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$10.48 Billion ≈ $330.09 Million |
-18.15% |
| 2024-12-31 | NT$12.80 Billion ≈ $403.27 Million |
-11.71% |
| 2023-12-31 | NT$14.50 Billion ≈ $456.74 Million |
-2.57% |
| 2022-12-31 | NT$14.88 Billion ≈ $468.80 Million |
+5.61% |
| 2021-12-31 | NT$14.09 Billion ≈ $443.89 Million |
+2.40% |
| 2020-12-31 | NT$13.76 Billion ≈ $433.50 Million |
+113.04% |
| 2019-12-31 | NT$6.46 Billion ≈ $203.48 Million |
+198.22% |
| 2018-12-31 | NT$2.17 Billion ≈ $68.23 Million |
-13.19% |
| 2017-12-31 | NT$2.49 Billion ≈ $78.60 Million |
-1.16% |
| 2016-12-31 | NT$2.52 Billion ≈ $79.53 Million |
-8.73% |
| 2015-12-31 | NT$2.77 Billion ≈ $87.13 Million |
+42.96% |
| 2014-12-31 | NT$1.93 Billion ≈ $60.95 Million |
-1.61% |
| 2013-12-31 | NT$1.97 Billion ≈ $61.94 Million |
+39.97% |
| 2012-12-31 | NT$1.40 Billion ≈ $44.26 Million |
+2.75% |
| 2011-12-31 | NT$1.37 Billion ≈ $43.07 Million |
+25.53% |
| 2010-12-31 | NT$1.09 Billion ≈ $34.31 Million |
-1.57% |
| 2009-12-31 | NT$1.11 Billion ≈ $34.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oneness Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7213.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Oneness Biotech Co Ltd Net Assets Breakdown (December 2025)
Oneness Biotech Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$11.37 Billion | 110.05% |
| Total Equity | NT$10.33 Billion | 100.00% |
Oneness Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Oneness Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JBG SMITH Properties
NYSE:JBGS
|
$692.08 Million |
|
Beijing E Hualu Info Tech
SHE:300212
|
$692.10 Million |
|
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
STU:2TZ
|
$692.11 Million |
|
Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A
SHG:603507
|
$692.28 Million |
|
Sapphire Foods India Limited
NSE:SAPPHIRE
|
$691.82 Million |
|
Zhongsheng Group Holdings Limited
F:5Z0
|
$691.82 Million |
|
Arctech Solar Holding Co Ltd
SHG:688408
|
$691.45 Million |
|
Guangdong Champion Asia Electronics Co Ltd
SHG:603386
|
$691.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oneness Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,298,878,000 to 10,331,643,000, a change of -1,967,235,000 (-16.0%).
- Net loss of 1,044,773,000 reduced equity.
- New share issuances of 30,522,000 increased equity.
- Other factors decreased equity by 952,984,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.04 Billion | -10.11% |
| Share Issuances | NT$30.52 Million | +0.3% |
| Other Changes | NT$-952.98 Million | -9.22% |
| Total Change | NT$- | -16.00% |
Book Value vs Market Value Analysis
This analysis compares Oneness Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.02x to 2.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$11.41 | NT$45.80 | x |
| 2010-12-31 | NT$6.22 | NT$45.80 | x |
| 2011-12-31 | NT$7.58 | NT$45.80 | x |
| 2012-12-31 | NT$7.22 | NT$45.80 | x |
| 2013-12-31 | NT$9.98 | NT$45.80 | x |
| 2014-12-31 | NT$10.08 | NT$45.80 | x |
| 2015-12-31 | NT$12.94 | NT$45.80 | x |
| 2016-12-31 | NT$11.34 | NT$45.80 | x |
| 2017-12-31 | NT$10.52 | NT$45.80 | x |
| 2018-12-31 | NT$9.08 | NT$45.80 | x |
| 2019-12-31 | NT$22.14 | NT$45.80 | x |
| 2020-12-31 | NT$33.58 | NT$45.80 | x |
| 2021-12-31 | NT$32.32 | NT$45.80 | x |
| 2022-12-31 | NT$32.63 | NT$45.80 | x |
| 2023-12-31 | NT$29.69 | NT$45.80 | x |
| 2024-12-31 | NT$25.73 | NT$45.80 | x |
| 2025-12-31 | NT$21.56 | NT$45.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oneness Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -809.13%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.14x
- Recent ROE (-10.11%) is below the historical average (-2.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.57% | 385.04% | 0.00x | 1.01x | NT$-104.37 Million |
| 2010 | 0.09% | 1.61% | 0.05x | 1.02x | NT$-107.95 Million |
| 2011 | 1.02% | 375.67% | 0.00x | 1.01x | NT$-122.76 Million |
| 2012 | -1.95% | -318.60% | 0.01x | 1.02x | NT$-167.86 Million |
| 2013 | 14.05% | 5993.77% | 0.00x | 1.06x | NT$79.64 Million |
| 2014 | 10.32% | 3645.30% | 0.00x | 1.04x | NT$6.27 Million |
| 2015 | -3.36% | -1186.29% | 0.00x | 1.02x | NT$-369.58 Million |
| 2016 | -0.56% | -249.99% | 0.00x | 1.01x | NT$-266.68 Million |
| 2017 | -6.62% | -6008.74% | 0.00x | 1.07x | NT$-390.31 Million |
| 2018 | -11.60% | -1248.60% | 0.01x | 1.15x | NT$-438.43 Million |
| 2019 | -5.19% | -2437.57% | 0.00x | 1.10x | NT$-961.12 Million |
| 2020 | -1.85% | -604.92% | 0.00x | 1.13x | NT$-1.61 Billion |
| 2021 | -2.95% | -627.72% | 0.00x | 1.12x | NT$-1.81 Billion |
| 2022 | 2.46% | 33.78% | 0.07x | 1.07x | NT$-1.10 Billion |
| 2023 | -9.34% | -1512.82% | 0.01x | 1.09x | NT$-2.72 Billion |
| 2024 | -9.47% | -988.03% | 0.01x | 1.11x | NT$-2.40 Billion |
| 2025 | -10.11% | -809.13% | 0.01x | 1.14x | NT$-2.08 Billion |
Industry Comparison
This section compares Oneness Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,553,984,800
- Average return on equity (ROE) among peers: 10.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oneness Biotech Co Ltd (4743) | NT$10.39 Billion | 0.57% | 0.08x | $691.90 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $91.32 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.96 Billion | 0.35% | 0.61x | $183.06 Million |
| Panion & BF Biotech Inc (1760) | $1.35 Billion | 11.79% | 0.36x | $135.06 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.82 Billion | 4.71% | 0.89x | $78.27 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.98 Billion | 8.93% | 0.46x | $107.90 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $31.29 Million |
| GenMont Biotech Inc (3164) | $1.45 Billion | 3.97% | 0.08x | $45.80 Million |
| Medigen Biotechnology (3176) | $539.65 Million | 8.19% | 0.26x | $145.71 Million |
| Sagittarius Life Science (3205) | $714.71 Million | 42.07% | 0.58x | $97.36 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.43 Billion | 2.72% | 0.10x | $115.03 Million |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, whic… Read more